Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof of concept, 48-week Multicenter, Randomized, evaluator-blinded, Phase 2a study in upper extremity nerve transections comparing NTX-001 adjunctive to standard of care (SOC) to SOC alone

Next Previous
Trial Profile

A proof of concept, 48-week Multicenter, Randomized, evaluator-blinded, Phase 2a study in upper extremity nerve transections comparing NTX-001 adjunctive to standard of care (SOC) to SOC alone

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NTX-001 Neuraptive Therapeutics (Primary)
  • Indications Peripheral nerve injuries; Peripheral neuropathies
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms NEUROFUSE

Most Recent Events

  • 19 Sep 2024 According to a Neuraptive Therapeutics, Inc media release, company announced that interim topline results from its ongoing Phase 2 NEUROFUSE Study will be presented at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting, held September 19-21 in Minneapolis, MN.
  • 11 Sep 2024 According to a Neuraptive Therapeutics, Inc media release, company announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair following the results from this trial.
  • 22 Feb 2024 According to a Neuraptive Therapeutics, Inc media release, top-line results will be presented at an upcoming scientific conference, and an End of Phase 2 meeting with the FDA anticipated in the near future to discuss late-phase development and the approval pathway.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top